S-18326

S-18326 is an orally active direct thrombin inhibitor. S-18326 inhibits thrombus formation by reversibly and with high affinity binding to the active site of thrombin, directly preventing the conversion of fibrinogen to fibrin. S-18326 effectively prolongs various clotting times in human plasma. S-18326 has demonstrated antithrombotic efficacy in multiple animal models without causing thrombocytopenia. S-18326 can be used in research on thromboembolic diseases[1].

167843-21-2

12352005

H302-H315-H319-H335

Thrombin

Metabolic Enzyme/Protease

Cardiovascular Disease

O=C(N(C1CCCC1)CC(N[C@@H](CCCNC(N)=N)B(O)O)=O)[C@H](NC(C)=O)CC2=CC=CC=C2

C23H37BN6O5

488.39

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

[1]De Nanteuil G, Verbeuren TJ. S 18326: a thrombin inhibitor that shows potential for oral treatment of thromboembolic disorders. Expert Opin Investig Drugs. 1999 Feb;8 (2) :173-80.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-19220/

Reference compound2

Phase 1